T. Witthoeft

958 total citations · 1 hit paper
12 papers, 803 citations indexed

About

T. Witthoeft is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, T. Witthoeft has authored 12 papers receiving a total of 803 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 9 papers in Epidemiology and 1 paper in Surgery. Recurrent topics in T. Witthoeft's work include Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (7 papers) and Hepatitis B Virus Studies (5 papers). T. Witthoeft is often cited by papers focused on Hepatitis C virus research (11 papers), Liver Disease Diagnosis and Treatment (7 papers) and Hepatitis B Virus Studies (5 papers). T. Witthoeft collaborates with scholars based in Germany, United States and Switzerland. T. Witthoeft's co-authors include Martín Steffen, Stefan Schreiber, Richard P. MacDermott, Andreas Raedler, R Heyne, Bernd Moeller, C John, D. Hueppe, G Teuber and Axel Baumgarten and has published in prestigious journals such as Journal of Hepatology, World Journal of Gastroenterology and Clinical & Experimental Immunology.

In The Last Decade

T. Witthoeft

10 papers receiving 784 citations

Hit Papers

Enhand secretion of tumour necrosis factor-alpha, IL-6, a... 1993 2026 2004 2015 1993 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease
    1993 728 citations Martín Steffen, T. Witthoeft et al. Clinical & Experimental Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
T. Witthoeft Germany 6 422 321 273 172 152 12 803
G.C. Naccari Italy 5 320 0.8× 268 0.8× 175 0.6× 218 1.3× 154 1.0× 5 762
Daniel A. Giles United States 13 170 0.4× 265 0.8× 374 1.4× 201 1.2× 112 0.7× 19 804
Magali de Bruyn Belgium 13 479 1.1× 200 0.6× 299 1.1× 228 1.3× 211 1.4× 31 836
Debra L. Robson Canada 8 262 0.6× 102 0.3× 260 1.0× 180 1.0× 88 0.6× 9 619
Maria Carme Masamunt Spain 16 756 1.8× 364 1.1× 409 1.5× 327 1.9× 341 2.2× 39 1.3k
Qi Yu China 14 254 0.6× 450 1.4× 117 0.4× 142 0.8× 72 0.5× 25 819
H Schmitt Germany 10 288 0.7× 305 1.0× 150 0.5× 168 1.0× 89 0.6× 49 640
G. Kojouharoff Germany 14 235 0.6× 326 1.0× 147 0.5× 224 1.3× 150 1.0× 22 932
Ying-Chao Lin Taiwan 8 424 1.0× 138 0.4× 312 1.1× 243 1.4× 135 0.9× 13 722
Christoffer Soendergaard Denmark 15 299 0.7× 97 0.3× 103 0.4× 309 1.8× 175 1.2× 21 879

Countries citing papers authored by T. Witthoeft

Since Specialization
Citations

This map shows the geographic impact of T. Witthoeft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Witthoeft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Witthoeft more than expected).

Fields of papers citing papers by T. Witthoeft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Witthoeft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Witthoeft. The network helps show where T. Witthoeft may publish in the future.

Co-authorship network of co-authors of T. Witthoeft

This figure shows the co-authorship network connecting the top 25 collaborators of T. Witthoeft. A scholar is included among the top collaborators of T. Witthoeft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Witthoeft. T. Witthoeft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Petersen, J., Thomas A. Lutz, Axel Baumgarten, et al.. (2012). 1149 PREDICTIVE FACTORS FOR NONRESPONSE IN GENOTYPE 2/3 INFECTED CHRONIC HEPATITIS C (CHC) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN REAL LIFE SETTING. Journal of Hepatology. 56. S454–S454. 1 indexed citations
2.
Craxı̀, Antonio, Liliana Chemello, Mojca Matičič, et al.. (2011). Peginterferon alfa‐2b plus weight‐based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response. Journal of Viral Hepatitis. 19(2). e120–5. 5 indexed citations
3.
4.
Hueppe, D., C John, R Heyne, et al.. (2010). Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. Journal of Viral Hepatitis. 18(4). e81–90. 19 indexed citations
5.
Witthoeft, T., D. Hueppe, C John, et al.. (2010). Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study. Journal of Viral Hepatitis. 17(7). 459–68. 23 indexed citations
6.
Hueppe, D., C John, Urs Meyer, et al.. (2008). 811 ESTIMATING THE LIKELIHOOD OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (CHC) THERAPY. Journal of Hepatology. 48. S303–S304.
7.
Witthoeft, T., D. Hueppe, C John, et al.. (2008). 840 EFFICACY AND SAFETY OF PEGINTERFERON ALFA-2a OR -2b PLUS RIBAVIRIN IN THE ROUTINE DAILY TREATMENT OF CHRONIC HEPATITIS C PATIENTS IN GERMANY: THE PRACTICE STUDY. Journal of Hepatology. 48. S315–S315. 14 indexed citations
8.
Erhardt, Andreas, Wulf O. Boecher, Heiner Wedemeyer, et al.. (2007). [226] LONG-TERM TREATMENT WITH PEG-IFN-ALFAb REDUCES HEPATOCELLULAR INCIDENCE AND PREVENTS CLINICAL COMPLICATIONS IN HEPATITIS C CIRRHOSIS - AN INTERIM ANALYSIS OF A MULTICENTER TRIAL. Journal of Hepatology. 46. S93–S93. 2 indexed citations
9.
10.
11.
Hueppe, D., E Zehnter, Michael P. Manns, et al.. (2007). Treatment and Outcome of Genotype 4 Chronic Hepatitis C Patients With PegInterferon alfa 2b and Ribavirin in the Clinical Setting in Germany. 1 indexed citations
12.
Steffen, Martín, et al.. (1993). Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease. Clinical & Experimental Immunology. 94(1). 174–181. 728 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G.C. Naccari Breakdown of academic impact, for papers by Daniel A. Giles Breakdown of academic impact, for papers by Magali de Bruyn Breakdown of academic impact, for papers by Debra L. Robson Breakdown of academic impact, for papers by Maria Carme Masamunt Breakdown of academic impact, for papers by Qi Yu Breakdown of academic impact, for papers by H Schmitt Breakdown of academic impact, for papers by G. Kojouharoff Breakdown of academic impact, for papers by Ying-Chao Lin Breakdown of academic impact, for papers by Christoffer Soendergaard
Rankless by CCL
2026